The post XION Unveils Infrastructure to Foster Email Verification Via ZK Tech at Scale appeared on BitcoinEthereumNews.com. The XION chain has unveiled the ZK ModuleThe post XION Unveils Infrastructure to Foster Email Verification Via ZK Tech at Scale appeared on BitcoinEthereumNews.com. The XION chain has unveiled the ZK Module

XION Unveils Infrastructure to Foster Email Verification Via ZK Tech at Scale

  • The XION chain has unveiled the ZK Module and DKIM Module to foster scalable email verification.
  • The Circle-backed L1 chain already serves over 800,000 monthly active users 
  • The future growth prospects for XION are bolstered by the rising demand for human verification in the AI era.

XION (XION) has launched the first onchain Zero Knowledge (ZK) email verification. This layer one (L1) blockchain focused on turning verified day into programmable value has announced the strategic launch of its ZK Module and DKIM Module to catalyze privacy-centric communication at scale.

“XION becomes the first blockchain to store email verification keys on-chain. Combined with protocol-level zero-knowledge verification, you can now prove any claim from your email without revealing the email itself,” the announcement stated.

XION Unveils ZK and DKIM Modules With Robust Community 

The XION blockchain unveiled the ZK and DKIM modules with a huge backing from the community. XION already serves more than 800,000 monthly active users with the integration of Gmail and Apple Mail supported. 

As such, XION has a ready market of more than 3.8 billion global users through its integration with Gmail and Apple Mail. Most importantly, more than 150 brands – led by Uber, Amazon, and BMW – are already building consumer applications based on the XION infrastructure.

The XION blockchain is backed by top Web3 investors led by Circle Internet Group Inc. (NYSE: CRCL), Hashkey, and Arrington Capital. XION’s ZK and DKIM’s modules could help catalyze the mainstream organic adoption of blockchain and digital assets in the long term, especially after raising over $36 million from these investors.

Key Use Cases

The use cases for XION’s ZK and DKIM Modules vary, but all of them revolve around zero-knowledge proofs. For instance, a whistleblower can now tap into XION’s ZK and DKIM Modules to remain anonymous, whereby they can prove selected information.

The XION’s ZK and DKIM modules are also useful in verifying anonymous workplace reviews from confirmed employees. In the web3 space, the new XION’s email verification infrastructure helps to back up crypto wallets’ recovery seed phrases. 

Other notable use cases for this tech debut on the blockchain include private credential verification, trustless ticket resale platforms, and the insurance claims industry.

“The trust problem isn’t going away. AI is making it exponentially worse every month. But the solution was already sitting in your inbox, waiting for the infrastructure to make it usable,” the announcement stated.

Why Now?

According to Burnt Banksy, the founder of XION network, the strategic launch of XION’s ZK and DKIM Modules aligns with the growing needs for privacy-centric communications. Furthermore, the DomainKeys Identified Mail (DKIM) tech has existed for more than two decades but still carries notable risks, especially due to the centralization of servers.

“Every other email verification system pulls keys from DNS – centralized servers that can change, disappear, or be censored. XION stores them permanently on-chain. trustless. verifiable by anyone. controlled by no one,” the XION team noted.

Source: https://www.livebitcoinnews.com/xion-unveils-infrastructure-to-foster-email-verification-via-zk-tech-at-scale/

Market Opportunity
XION Logo
XION Price(XION)
$0.1158
$0.1158$0.1158
-1.53%
USD
XION (XION) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26